| 1. | Sakorafas GH, Krespis E, Pavlakis G. Risk estimation for breast cancer development; a clinical perspective [J]. Surg Oncol, 2002; 10(4)∶183. | 
				                                                        
				                                                            
				                                                                | 2. | 吳揚, 楊莉, 魏于全. 乳腺癌相關基因的分子遺傳學研究進展 [J]. 中華醫學遺傳學雜志, 2002; 19(2)∶152. | 
				                                                        
				                                                            
				                                                                | 3. | Sorokin P. New agents and future directions in biotherapy [J]. Clin J Oncol Nurs, 2002; 6(1)∶19. | 
				                                                        
				                                                            
				                                                                | 4. | Knutson KL, Bishop MR, Schiffman K, et al. Immunotherapy for breast cancer [J]. Cancer Chemother Biol Response Modif, 2002; 20∶351. | 
				                                                        
				                                                            
				                                                                | 5. | Untch M, Ditsch N, Hermelink K. Immunotherapy: new options in breast cancer treatment [J]. Expert Rev Anticancer Ther, 2003; 3(3)∶403. | 
				                                                        
				                                                            
				                                                                | 6. | Menard S, Fortis S, Castiglioni F, et al. HER2 as a prognostic factor in breast cancer [J]. Oncology, 2001; 61 Suppl 2∶67. | 
				                                                        
				                                                            
				                                                                | 7. | Goldenberg MM. Trastuzumab, a recombinant DNAderived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer [J]. Clin Ther, 1999; 21(2)∶309. | 
				                                                        
				                                                            
				                                                                | 8. | Ligibel JA, Winer EP. Trastuzumab/chemotherapy combinations in metastatic breast cancer [J]. Semin Oncol, 2002; 29(3 Suppl 11)∶38. | 
				                                                        
				                                                            
				                                                                | 9. | Christodoulou C, Klouvas G, Pateli A, et al. Prolonged administration of weekly paclitaxel and trastuzumab in patients with advanced breast cancer [J]. Anticancer Res, 2003; 23(1B)∶737. | 
				                                                        
				                                                            
				                                                                | 10. | Avigan D. Fusions of breast cancer and dendritic cells as a novel cancer vaccine [J]. Clin Breast Cancer, 2003; 3 Suppl 4∶S158. | 
				                                                        
				                                                            
				                                                                | 11. | Pulaski BA, OstrandRosenberg S. Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cellbased tumor vaccines [J]. Cancer Res, 1998; 58(7)∶1486. | 
				                                                        
				                                                            
				                                                                | 12. | Wu Q, Moyana T, Xiang J. Cancer gene therapy by adenovirusmediated gene transfer [J]. Curr Gene Ther, 2001; 1(1)∶101. | 
				                                                        
				                                                            
				                                                                | 13. | Dummer R, Bergh J, Karlsson Y, et al. Biological activity and safety of adenoviral vectorexpressed wildtype p53 after intratumoral injection in melanoma and breast cancer patients with p53overexpressing tumors [J]. Cancer Gene Ther, 2000; 7(7)∶1069. | 
				                                                        
				                                                            
				                                                                | 14. | Bougeret C, VironeOddos A, Adeline E, et al. Cancer gene therapy mediated by CTS1, a p53 derivative: advantage over wildtype p53 in growth inhibition of human tumors overexpressing MDM2 [J]. Cancer Gene Ther, 2000; 7(5)∶789. | 
				                                                        
				                                                            
				                                                                | 15. | Takahashi S, Hatake K, Sugimoto Y. Gene therapy for breast cancer [J]. Gan To Kagaku Ryoho, 2003; 30(4)∶468. | 
				                                                        
				                                                            
				                                                                | 16. | Tallman MS, Gray R, Robert NJ, et al. Conventional adjuvant chemotherapy with or without highdose chemotherapy and autologous stemcell transplantation in highrisk breast cancer [J]. N Engl J Med, 2003; 349(1)∶17. | 
				                                                        
				                                                            
				                                                                | 17. | Harris AL, Zhang H, Moghaddam A, et al. Breast cancer angiogenesisnew approaches to therapy via antiangiogenesis, hypoxic activated drugs, and vascular targeting [J]. Breast Cancer Res Treat, 1996; 38(1)∶97. | 
				                                                        
				                                                            
				                                                                | 18. | Ranieri G, Gasparini G. Angiogenesis and angiogenesis inhibitors: a new potential anticancer therapeutic strategy [J]. Curr Drug Targets Immune Endocr Metabol Disord, 2001; 1(3)∶241. |